AL-ADTRAN
13.6.2024 14:01:33 CEST | Business Wire | Press release
Adtran today launched two new optical cesium atomic clocks that set new standards in network time synchronization: the OSA 3300 Super High-Performance (OSA 3300 SHP) and the OSA 3350 Super Enhanced Primary Reference Clock+ (OSA 3350 SePRC+). As part of Adtran’s Oscilloquartz portfolio of industry-first optical cesium clocks, the devices leverage unique, state-of-the-art optical pumping technology to meet evolving demands across applications from scientific research to critical PNT infrastructure. The OSA 3300 SHP offers exceptional stability and accuracy, making it a valuable tool for metrology institutes and scientific research facilities. In contrast, the OSA 3350 SePRC+ is specifically designed to enhance holdover capabilities for PNT services. It maintains 100 days of 100-nanosecond precision, providing continuous and accurate timing even in environments where GPS/GNSS is unavailable. This makes it a crucial component for ensuring the integrity of mission-critical networks and supporting vital infrastructure and defense operations with reliable backup timing.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240613778509/en/
Adtran’s new optical pumping cesium clocks are a significant breakthrough for the networking industry. (Photo: Business Wire)
“Our two new optical cesium clocks represent a major breakthrough, offering substantial benefits to a wide variety of industries. Take the OSA 3350 SePRC+, for instance – it ensures 100-nanosecond accuracy over a span of more than three months. This level of precision and stability is critical for infrastructures relying on continuous PNT services, providing our customers with supreme reliability and robust protection against escalating cyber threats to GPS/GNSS,” said Gil Biran, GM of Oscilloquartz, Adtran. “In an era marked by rising global tensions and heightened risks of state-sponsored interference in satellite communications, our latest innovation has arrived at a pivotal moment. It will greatly enhance our capacity to address the demand for secure and reliable network timing around the world. Building on our 75-year legacy and unmatched expertise, the OSA 3350 SePRC+ exemplifies our commitment to excellence in assured PNT technology. As pioneers in the field, we continue to set new benchmarks, consistently improving standards to meet the dynamic needs of our customers and the broader market.”
The OSA 3300 SHP and OSA 3350 SePRC+ redefine the capabilities of PRCs and ePRCs, unlocking new possibilities in their respective domains. The OSA 3300 SHP, with its superior Allan Deviation (ADEV) performance – twice as accurate as the 3300 HP with the same 10-year lifespan – ensures exceptional stability and accuracy, making it an ideal choice for metrology institutes and scientific research facilities. Its advanced feature set enables these institutions to achieve new levels of precision in their timekeeping and calibration processes, directly driving advancements in scientific research and industrial applications. Meanwhile, the OSA 3350 SePRC+ is specifically designed to enhance holdover capabilities for PNT services. This high-end optical cesium clock, together with our Super ePRTC+ combiner can maintain 100 days of 100-nanosecond precision, far exceeding previous industry records, and ensuring continuous and accurate timing even in environments where GPS/GNSS are unavailable.
“Our OSA 3300 SHP provides unprecedented accuracy in timekeeping, maintaining nanosecond precision over extended periods. This level of enhanced accuracy and stability is crucial for scientific research and metrology, supporting high-precision experiments and the calibration of instruments to the highest standards. The 3300 SHP allows researchers to conduct groundbreaking experiments in fields like quantum mechanics and relativity, where extreme accuracy is paramount,” commented Patrick Berthoud, time and frequency chief scientist at Oscilloquartz, Adtran. “At Oscilloquartz, we’re dedicated to advancing time and frequency technology, leveraging our world-renowned Swiss expertise in this field. Our latest innovations demonstrate our commitment to delivering superior solutions that meet the evolving demands of our customers, driving progress in both scientific research and industrial applications.”
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
Published by
ADTRAN Holdings, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240613778509/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
